US Patent 8,513,249: Brimonidine Gel Claims, Patent Scope, Orange Book Status and Generic Entry Risk

US Patent 8,513,249 protects methods and topical compositions using approximately 0.4% to 0.6% brimonidine, including 0.5% brimonidine tartrate, to treat erythema, particularly rosacea-associated facial erythema. The patent combines three principal limitations: a narrow active-ingredient concentration, pharmacokinetic exposure ceilings, and clinical performance requirements for sustained 12-hour erythema improvement.

The patent is closely associated with Galderma’s Mirvaso, a prescription brimonidine tartrate gel approved by the FDA for persistent facial erythema of rosacea. Its practical commercial value is concentrated in claims covering the 0.5% brimonidine tartrate gel strength, once-daily administration, and the resulting pharmacokinetic and clinical profile.

What does US Patent 8,513,249 protect?

US Patent 8,513,249 protects three categories of subject matter:

Claim category	Claims	Core protection
Methods of treatment	1-13, 20	Topical treatment of erythema using 0.4%-0.6% brimonidine and specified systemic exposure
Packaged product	14	Composition, treatment instructions and unified packaging
Topical compositions	15-19, 21-22	Brimonidine gel compositions with pharmacokinetic and clinical-performance limitations

The independent claims are claims 1, 14 and 15.

Claim 1 is the principal method claim. It requires:

A subject with erythema or an associated symptom.
Topical administration to the affected skin area.
A composition containing 0.4%-0.6% brimonidine by weight.
A pharmaceutically acceptable carrier.
A serum or plasma mean Cmax of approximately 54 ± 28 pg/mL or less.
A mean 24-hour AUC of approximately 568 ± 277 pg·hr/mL or less.

Claim 15 is the principal composition claim. It covers a topical gel composition with the same concentration and pharmacokinetic limitations. Claims 14 and 15 are important because they extend potential infringement theories beyond the physician’s treatment conduct.

How narrow are the concentration limitations?

The concentration limitation is central. The independent claims require 0.4%-0.6% brimonidine by weight. Dependent claims narrow that range to approximately 0.5% brimonidine tartrate.

Mirvaso contains 0.33% brimonidine equivalent as brimonidine tartrate, corresponding to approximately 0.5% brimonidine tartrate in the formulation. The patent claims therefore track the commercial product’s salt strength rather than only the free-base concentration.

Patent limitation	Commercial relevance
0.4%-0.6% brimonidine	Broad claimed concentration band
Approximately 0.5% brimonidine tartrate	Directly aligned with the marketed gel
0.33% brimonidine equivalent	Common labeling expression for Mirvaso
Topical gel	Covers the commercial dosage form
Pharmaceutically acceptable carrier	Requires a qualifying vehicle but leaves substantial formulation flexibility

A generic product labeled as 0.33% brimonidine tartrate may still fall within the patent claims if the formulation contains approximately 0.5% brimonidine tartrate and satisfies the claimed pharmacokinetic limitations.

What pharmacokinetic profile does the patent require?

The patent does not claim concentration alone. It requires a systemic exposure profile:

Pharmacokinetic parameter	Claimed ceiling
Mean Cmax	About 54 ± 28 pg/mL or less
Mean AUC0-24 hr	About 568 ± 277 pg·hr/mL or less

The claim language creates a technical infringement issue. The specification and prosecution history would determine whether “about 54 ± 28 pg/mL or less” means a nominal upper value, a range incorporating the standard deviation, or a mean target characterized by the stated variability. The same issue applies to the AUC limitation.

For a generic applicant, this limitation can create a factual dispute requiring comparative pharmacokinetic evidence. A product may match the active ingredient and strength but avoid infringement if its systemic exposure materially exceeds the claimed profile. Conversely, the branded sponsor could argue that a formulation with the same composition and comparable bioavailability inherently meets the limitation.

The pharmacokinetic limitation also makes the patent less vulnerable to a simple formulation design-around. Changing excipients or rheology may affect absorption, but the resulting product must still deliver adequate local efficacy while avoiding the claimed exposure profile.

What clinical efficacy does US 8,513,249 require?

Claims 5, 6, 21 and 22 add a 12-hour clinical success profile. The required result includes:

At least a one-grade improvement in erythema or its symptom.
Approximately one to eight hours of two-grade improvement.
Evaluation using both Clinician’s Erythema Assessment scores and Patient’s Self Assessment scales.

For facial erythema associated with rosacea, claim 6 narrows the two-grade improvement period to approximately three to six hours.

These claims are result-oriented limitations. They do not merely require administration of the gel. They require a demonstrated clinical response compared with a vehicle control. The claims therefore have a higher evidentiary burden in litigation than claims based only on composition.

A generic product used for the same indication could face two separate disputes:

Whether its formulation necessarily produces the claimed pharmacokinetic profile.
Whether the labeled method of use necessarily produces the claimed 12-hour clinical response.

The second issue may depend on clinical trial data, product labeling, formulation equivalence and whether the claimed result is inherent in the approved use.

What formulations are protected by US 8,513,249?

The dependent claims identify several formulation features:

Claim	Formulation limitation
7-8	Brimonidine tartrate, including approximately 0.5% by weight
9-10	0.50%-2.0% gelling agent containing carbomer
10	Carbomer 934P, 974P or 980
11	0.04%-0.08% water-dispersible titanium dioxide
12	Specified preservatives
13, 19	5.0%-15.0% of at least one polyol

These limitations provide fallback positions if the broader independent claims are invalidated or avoided. A product containing a listed carbomer, titanium dioxide, preservative or polyol could fall within one or more dependent claims if it also satisfies the independent claim requirements.

The formulation claims are not limited to one exact commercial recipe. They cover ranges and alternatives. A competitor may attempt to avoid them by selecting a different gelling polymer, preservative system, opacifying agent or humectant. That approach may avoid a dependent claim while leaving the independent concentration and pharmacokinetic claims in place.

When does US Patent 8,513,249 lose exclusivity?

The patent’s expected expiration is December 21, 2027, based on the underlying US priority and patent-term framework associated with the Mirvaso brimonidine patent family. The exact enforceable date must be confirmed against the USPTO patent-term adjustment calculation, any terminal disclaimer and current patent records.

Event	Timing
Priority family	2007-era brimonidine topical formulation and treatment filings
US patent grant	August 20, 2013
Expected nominal expiration	December 21, 2027
Relevant FDA product	Mirvaso, brimonidine tartrate topical gel
Regulatory exclusivity	Separate from patent term and generally expired before the patent term

FDA drug exclusivity and patent exclusivity are separate. Mirvaso’s new-drug exclusivity period did not determine the 2027 patent date. Generic approval could be delayed by listed patents, patent litigation, settlement terms or the statutory 30-month stay following a Paragraph IV notice.

What is the Orange Book status of US 8,513,249?

US Patent 8,513,249 has been associated with the Mirvaso patent estate and is relevant to Orange Book patent analysis for brimonidine tartrate gel. Orange Book relevance depends on whether the patent is listed against the approved product and whether the listed claims cover the approved drug, its formulation or an approved method of use.

The relevant product is:

FDA product	Active ingredient	Dosage form	Indication
Mirvaso	Brimonidine tartrate	Topical gel, 0.33% brimonidine equivalent	Persistent facial erythema of rosacea

The patent’s composition and method-of-use claims fit the types of claims generally considered for Orange Book listing. A current Orange Book review should be performed against the product’s FDA application record because listing status can change through patent expiration, delisting, correction or regulatory updates.[1]

Other patents in the Mirvaso estate may be more important for a particular generic filing. A Paragraph IV analysis must examine every currently listed patent, not US 8,513,249 in isolation.

Which patent families compete with US 8,513,249?

The commercial patent landscape includes several related US patents directed to brimonidine topical products, compositions, treatment methods and clinical performance. The principal related patent commonly identified with the Mirvaso estate is US Patent 8,420,850, which covers topical brimonidine compositions and related formulation subject matter.

Patent	General subject matter	Commercial significance
US 8,420,850	Topical brimonidine composition and formulation technology	May protect the product architecture and vehicle
US 8,513,249	Erythema treatment, pharmacokinetics and clinical response	Directly targets treatment with the commercial strength
Related continuation or divisional patents	Treatment, composition or use limitations	May create layered generic-entry barriers
FDA-listed Mirvaso patents	Product, formulation and method-of-use claims	Determine Paragraph IV litigation exposure

The family structure matters. A continuation may issue with narrower claims after a parent patent has been challenged. A generic entrant must review the complete family, prosecution history, terminal disclaimers and patent listings.

What Paragraph IV challenges affect brimonidine gel?

A generic applicant seeking approval before patent expiration could file an ANDA with a Paragraph IV certification against listed Mirvaso patents. The certification would state that the relevant patent is invalid, unenforceable or not infringed.

A Paragraph IV dispute involving US 8,513,249 would likely focus on:

Anticipation and obviousness

Prior art could include:

Earlier ophthalmic brimonidine products.
Alpha-2 adrenergic agonist treatment of erythema.
Earlier topical gel vehicles.
Clinical studies involving brimonidine concentrations.
Prior pharmacokinetic and tolerability data.

The strongest validity question is whether the prior art disclosed the combination of the claimed concentration, low systemic exposure and sustained erythema improvement. Prior art disclosing brimonidine generally would not necessarily disclose the claimed PK and clinical-result limitations.

Written description and enablement

The challenger could argue that the patent does not adequately support every composition within the 0.4%-0.6% range or every carrier producing the claimed PK profile. The patentee would rely on examples, formulation disclosure and clinical data showing that the claimed range was linked to the stated efficacy and exposure.

Claim construction

The terms “about,” “or less,” “mean Cmax,” “mean AUC” and “12 hour success profile” would be central. Claim construction could determine whether the patent covers a generic product whose average exposure is close to, but outside, the stated values.

Induced infringement

Even if a generic label omits a patented indication, infringement risk can remain if the product’s labeling, prescribing information or promotional materials encourage the patented rosacea treatment. Method-of-use claims are particularly sensitive to the content of the proposed label.

No specific Paragraph IV settlement terms should be assumed without a verified court docket, ANDA notice record or public settlement disclosure. FDA approval of a generic product also does not establish that every listed patent has been invalidated.

How strong is the patent estate for Mirvaso?

US 8,513,249 is commercially meaningful but technically narrower than a simple composition patent. Its strength comes from the combination of:

A concentration range aligned with the marketed product.
A salt-specific dependent claim covering 0.5% brimonidine tartrate.
Low systemic-exposure limitations.
Clinical efficacy requirements.
Additional formulation fallback claims.

Its principal vulnerability is that the PK and clinical limitations can create proof and claim-construction disputes. The same limitations that distinguish the patent from broad prior art may make infringement more difficult to establish against a formulation with different excipients or absorption characteristics.

Strength factor	Assessment
Alignment with marketed product	High
Breadth of composition coverage	Moderate
Breadth of treatment coverage	Moderate
Dependence on clinical data	High
Design-around potential	Moderate
Generic litigation complexity	High
Expected remaining term	Through December 2027, subject to official term calculation

What generic launch scenarios exist?

Launch after patent expiration

This is the lowest-risk path if all listed Mirvaso patents expire by December 2027 and no additional enforceable patents remain.

Paragraph IV launch after litigation

A generic applicant could challenge the patent and launch after a favorable judgment, a settlement permitting entry, or expiration of the 30-month stay without an injunction. The commercial timing would depend on the full Orange Book portfolio.

At-risk launch

A generic company could launch before final resolution. That would expose it to damages, an injunction and possible loss of market access if the patentee prevails.

Non-infringing formulation

A competitor could attempt to use a different gel system or excipient profile. That strategy would need to avoid both the composition limitations and the claimed PK and clinical outcomes. A formulation that remains bioequivalent to Mirvaso may still create an inherent-infringement dispute.

What manufacturing and geographic IP barriers remain?

The patent is a US right. It does not directly block manufacture or sale outside the United States. Foreign family members may protect corresponding products in Europe, Canada, Japan and other markets, but each jurisdiction requires separate review of validity, enforceability and expiration.

Manufacturing barriers may arise from:

The need to produce a stable brimonidine gel.
Control of active concentration and uniformity.
Preservation and microbial limits.
Carbomer selection and neutralization.
Scale-up effects on viscosity and drug release.
Demonstration of comparable pharmacokinetics.
FDA chemistry, manufacturing and controls requirements.

Patent protection does not replace FDA approval requirements. An ANDA applicant must satisfy pharmaceutical equivalence, bioequivalence, manufacturing and labeling requirements even if it establishes that the patents are invalid or not infringed.[2]

How does US 8,513,249 compare with a broad formulation patent?

A broad formulation patent typically focuses on ingredients and ranges. US 8,513,249 combines formulation, treatment and outcome limitations.

Feature	US 8,513,249	Typical broad formulation patent
Active concentration	Narrow, product-aligned range	May be broader
Dosage form	Topical gel or composition	Usually specified
Pharmacokinetics	Expressly required	Often absent
Clinical outcome	Expressly required in dependent claims	Often absent
Design-around	Possible through vehicle and PK changes	Often more difficult if claims are broad
Litigation proof	Requires technical and clinical evidence	Primarily formulation comparison

Key Takeaways

US 8,513,249 is directed to topical brimonidine treatment and composition claims for erythema, especially rosacea-associated facial erythema.
The commercial core is approximately 0.5% brimonidine tartrate, corresponding to the marketed Mirvaso gel strength.
The independent claims require both the concentration range and specified low systemic brimonidine exposure.
Dependent claims add once-daily use, clinical improvement, carbomer, titanium dioxide, preservatives and polyols.
The expected patent expiration is December 21, 2027, subject to confirmation of official patent-term calculations.
Generic risk depends on the complete Orange Book portfolio, not this patent alone.
A Paragraph IV challenge would likely focus on obviousness, pharmacokinetic claim construction, inherency and the clinical-result limitations.
A formulation design-around may reduce risk under dependent claims but may not avoid the independent PK and concentration limitations.
The patent is strongest against a generic that reproduces the Mirvaso strength, indication, gel format and comparable systemic exposure.

FAQs

Does US 8,513,249 cover Mirvaso specifically?

It covers compositions and methods that meet the claimed limitations, including approximately 0.5% brimonidine tartrate, topical treatment of erythema and the stated pharmacokinetic profile. It does not depend solely on the Mirvaso trademark.

Is brimonidine tartrate the same as brimonidine in the patent claims?

The claims use “brimonidine” broadly and then expressly recite brimonidine tartrate in dependent claims. A product’s concentration must be analyzed on the same basis used by the claim and product labeling.

Can a generic avoid US 8,513,249 by changing the carbomer?

Possibly for claims specifically requiring carbomer 934P, 974P or 980. Changing the gelling agent does not automatically avoid the independent claims, which focus on brimonidine concentration, topical use and pharmacokinetic exposure.

Does a 30-month stay permanently block generic brimonidine gel approval?

No. The stay generally delays approval for the statutory period after a Paragraph IV notice, subject to litigation events and statutory exceptions. It does not extend the patent term permanently.

Are biosimilars relevant to Mirvaso?

No. Mirvaso is a small-molecule topical drug, not a biologic. Competition would proceed through the ANDA pathway for a generic drug, rather than the biosimilar pathway under the Public Health Service Act.

References

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov
U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,513,249, methods of treating erythema. U.S. Department of Commerce.
Galderma Laboratories, L.P. (2013). Mirvaso (brimonidine tartrate) gel prescribing information. U.S. Food and Drug Administration.
U.S. Food and Drug Administration. (1984). Hatch-Waxman Amendments, 21 U.S.C. §§ 355 and 360cc. https://www.fda.gov/ajax? Reverted?

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1631293	⤷ Start Trial	CR 2014 00031	Denmark	⤷ Start Trial
European Patent Office	1631293	⤷ Start Trial	C300683	Netherlands	⤷ Start Trial
European Patent Office	1631293	⤷ Start Trial	1490049-2	Sweden	⤷ Start Trial
European Patent Office	1631293	⤷ Start Trial	C20140022 00150	Estonia	⤷ Start Trial
European Patent Office	1631293	⤷ Start Trial	92462	Luxembourg	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,513,249

Which drugs does patent 8,513,249 protect, and when does it expire?

Summary for Patent: 8,513,249